Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$2.63 +2.7%	$2.85	$2.01 ▼ $6.33	$382.78M	2.02	6.56 million shs	3.85 million shs
NRC National Research	$15.37 +5.9%	$15.39	$9.76 ▼ $22.99	$334.65M	0.44	120,422 shs	83,241 shs
OCG Oriental Culture	$3.49 +26.9%	$5.21	$1.01 ▼ $7.47	$72.36M	0.56	39,507 shs	300,261 shs
OPRX OptimizeRx	$17.25 +6.9%	$13.97	$3.78 ▼ $18.22	$299.64M	1.33	427,113 shs	367,815 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	-0.39%	-14.67%	-29.48%	-3.76%	-41.15%
NRC National Research	-7.70%	-3.27%	+2.47%	+6.77%	-31.62%
OCG Oriental Culture	-11.00%	-27.63%	-50.45%	-53.23%	+129.17%
OPRX OptimizeRx	+4.20%	-8.24%	+21.35%	+38.54%	+88.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABSI Absci	2.9164 of 5 stars	3.5	2.0	0.0	2.1	3.3	0.6
NRC National Research	2.1841 of 5 stars	0.0	5.0	1.7	0.0	2.5	1.3
OCG Oriental Culture	0.2382 of 5 stars	0.0	2.0	0.0	0.0	1.7	0.6
OPRX OptimizeRx	1.2709 of 5 stars	1.4	3.0	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	3.00	Buy	$7.98	203.35% Upside
NRC National Research	0.00	N/A	N/A	N/A
OCG Oriental Culture	0.00	N/A	N/A	N/A
OPRX OptimizeRx	2.73	Moderate Buy	$11.81	-31.52% Downside

Current Analyst Ratings Breakdown

Latest OCG, ABSI, NRC, and OPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABSI Absci	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.40 ➝ $5.89
8/13/2025	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
8/11/2025	OPRX OptimizeRx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$14.00 ➝ $20.00
8/8/2025	OPRX OptimizeRx	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	OPRX OptimizeRx	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $18.00
7/28/2025	ABSI Absci	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$7.00 ➝ $6.40
7/3/2025	ABSI Absci	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/9/2025	OPRX OptimizeRx	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.50 ➝ $16.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$4.53M	86.81	N/A	N/A	$1.16 per share	2.27
NRC National Research	$143.06M	2.48	$1.41 per share	10.87	$0.92 per share	16.71
OCG Oriental Culture	$622.69K	116.21	N/A	N/A	$10.73 per share	0.33
OPRX OptimizeRx	$92.13M	3.48	N/A	N/A	$6.43 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$103.11M	-$0.94	N/A	N/A	N/A	-2,737.94%	-60.21%	-50.85%	N/A
NRC National Research	$24.78M	$0.76	20.22	∞	N/A	12.78%	83.52%	18.05%	10/24/2025 (Estimated)
OCG Oriental Culture	-$3.60M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OPRX OptimizeRx	-$18.66M	-$0.54	N/A	N/A	2.29	-9.42%	4.50%	3.12%	N/A

Latest OCG, ABSI, NRC, and OPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ABSI Absci	-$0.19	-$0.24	-$0.05	-$0.24	$1.39 million	$0.59 million
7/28/2025	Q2 2025	NRC National Research	N/A	$0.28	N/A	-$0.01	N/A	$34.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
NRC National Research	$0.48	3.12%	N/A	63.16%	N/A
OCG Oriental Culture	N/A	N/A	N/A	N/A	N/A
OPRX OptimizeRx	N/A	N/A	N/A	N/A	N/A

Latest OCG, ABSI, NRC, and OPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	NRC National Research	quarterly	$0.12	3.6%	9/26/2025	9/26/2025	10/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	4.39	4.39
NRC National Research	3.61	0.70	0.70
OCG Oriental Culture	N/A	15.99	N/A
OPRX OptimizeRx	0.21	2.57	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
NRC National Research	47.26%
OCG Oriental Culture	1.58%
OPRX OptimizeRx	76.47%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.49%
NRC National Research	8.10%
OCG Oriental Culture	23.87%
OPRX OptimizeRx	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	149.52 million	133.84 million	Optionable
NRC National Research	490	23.06 million	21.20 million	Optionable
OCG Oriental Culture	50	20.73 million	14.14 million	No Data
OPRX OptimizeRx	100	18.57 million	17.53 million	Optionable

OCG, ABSI, NRC, and OPRX Headlines

Recent News About These Companies

All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy

August 21 at 1:01 PM | zacks.com

Best Momentum Stock to Buy for August 21st

August 21 at 11:01 AM | zacks.com

OptimizeRx announces leadership team advancements

August 19 at 2:00 PM | msn.com

OptimizeRx Announces Leadership Changes for Strategic Growth

August 19 at 2:00 PM | msn.com

OptimizeRx Corp. Announces Leadership Changes to Enhance Growth Strategy and Profitability

August 19 at 8:11 AM | quiverquant.comQ

OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

August 19 at 7:30 AM | globenewswire.com

Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $11.81

August 19 at 2:17 AM | americanbankingnews.com

OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from Analysts

August 17, 2025 | marketbeat.com

OptimizeRx (NASDAQ:OPRX) Price Target Raised to $20.00

August 14, 2025 | americanbankingnews.com

OptimizeRx Earnings Call: Strong Growth and Positive Outlook

August 13, 2025 | msn.com

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

JMP Securities Raises OptimizeRx (NASDAQ:OPRX) Price Target to $20.00

August 12, 2025 | marketbeat.com

OptimizeRx Corp. (OPRX) Stock Price Today - WSJ

August 10, 2025 | wsj.com

Stifel Nicolaus Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock

August 9, 2025 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX) and Relay Therapeutics (RLAY)

August 9, 2025 | theglobeandmail.com

OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

OptimizeRx Corporation: OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

August 8, 2025 | finanznachrichten.de

OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

August 7, 2025 | globenewswire.com

Best Growth Stocks to Buy for August 7th

August 7, 2025 | zacks.com

OptimizeRx Corp. (NASDAQ:OPRX) Shares Bought by Blair William & Co. IL

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCG, ABSI, NRC, and OPRX Company Descriptions

Absci NASDAQ:ABSI

$2.63 +0.07 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$2.65 +0.02 (+0.61%)

As of 08:00 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

National Research NASDAQ:NRC

$15.37 +0.86 (+5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$15.44 +0.07 (+0.42%)

As of 04:32 PM Eastern

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Oriental Culture NYSE:OCG

$3.49 +0.74 (+26.91%)

As of 03:59 PM Eastern

Oriental Culture Holding LTD, through its subsidiaries, operates an online platform to facilitate e-commerce trading of artwork and collectables in China and Hong Kong. The company facilitates trading by individual and institutional customers of various collectibles, artworks, and commodities on its online platforms. It also provides online and offline integrated marketing, storage, and technical maintenance services. In addition, the company offers industry solutions and related software products, and system development and technical support services. Further, it is involved in the development of Wine and Spirits metaverse project. Oriental Culture Holding LTD was incorporated in 2018 and is headquartered in Central, Hong Kong.

OptimizeRx NASDAQ:OPRX

$17.25 +1.11 (+6.88%)

Closing price 04:00 PM Eastern

Extended Trading

$17.24 0.00 (-0.03%)

As of 06:47 PM Eastern

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time